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WHAT SORT OF PEOPLE DO WE WANT?
THE ETHICS OF CHANGING PEOPLE
THROUGH GENETIC ENGINEERING
MICHAEL J. REISS*
Within the last decade, genetic engineering has changed
from being a relatively esoteric research technique of molecular
biologists to an application of considerable power, yet one which
raises widespread public concern. In this article, I first briefly
summarize the principles of genetic engineering, as applied to
any organism. I then concentrate on humans, reviewing both
progress to date and possible future developments. Throughout,
my particular focus is on the ethical acceptability or otherwise of
the technology.
I restrict myself to cases where humans are themselves being
genetically engineered. This means, for instance, that I do not
cover such topics as xenotransplantation (when animals are
genetically engineered to make them suitable for transplantation
into humans) and the issues resulting from the production of
such products as genetically engineered human growth hor-
mone, al-antitrypsin, or vaccines (when micro-organisms, ani-
mals, or plants are genetically engineered to produce human
proteins). Nor do I cover cloning, which deserves an article all to
itself.
My three main conclusions are as follows: First, somatic gene
therapy (in which genetic alterations are made to the non-repro-
ductive cells of an individual for intended medical benefit) is
ethically fairly unproblematic and likely to be accepted by the
great majority of people. However, its scope is more limited than
is often supposed. Second, germ-line therapy (in which genetic
alterations are made to the reproductive cells of an individual for
intended medical benefit for him/herself and his/her descend-
ants) is currently too risky to be allowed. However, this will prob-
ably not always be the case. Third, the use of either somatic or
germ-line modification to enhance human traits such as person-
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ality, behavior, or intelligence, is highly controversial. At present
it is probably best to outlaw such practices.
I. PRINCIPLES OF GENETIC ENGINEERING
As is nowadays widely known, every organism carries inside
itself what are known as genes. These genes are codes or instruc-
tions: they carry information which is used to tell the organism
what chemicals it needs to make in order to survive, grow, and
reproduce. Most genes make proteins such as keratin (which is
found in hair and nails), actin and myosin (both found in mus-
cles), and all the various enzymes that control the rates at which
the chemical reactions in organisms take place. Genetic engi-
neering typically involves moving genes from one organism to
another. The result of this procedure, if all goes as intended, is
that the chemical normally made by the gene in the first organ-
ism is now made by the second.
A. The Basic Practices of Genetic Engineering
Suppose we want a species to produce a protein made by
another species. For example, we might want a bacterium to pro-
duce human insulin so as to be able to collect and then give the
insulin to people unable to make it for themselves. The basic
procedure, using genetic engineering, involves the following
steps:
1. Identify the gene that makes the protein we are inter-
ested in.
2. Transfer this gene from the species in which it occurs
naturally to the species in which we want the gene to
be.'
The first of these steps is more difficult than it may sound.
Even a bacterium has hundreds of different genes, while animals
and plants have tens of thousands or more. Humans probably
have around 80,000 to 100,000 genes.2 Nowadays, though, there
are a number of ways of identifying the gene that makes the pro-
tein in which one is interested.
Two different types of approaches can be used to carry out
the second step, namely transferring this gene from the species
in which it occurs naturally to the intended species recipient.
One involves the use of a vector organism to carry the gene; the
1. See generally DESMOND S.T. NICHOLL, AN INTRODUCTION TO GENETIC
ENGINEERING (1994).
2. See id. at 146.
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other, called vectorless transmission, is more direct and requires
no intermediary organism.
3
A vector carries genetic material from one species (the
donor species) to another (the genetically engineered species).
Genetic engineering by means of a vector involves three steps:
1. Obtain the desired piece of genetic material from the
donor species.
2. Insert this piece of genetic material into the vector.
3. Infect the species to be genetically engineered with the
vector so that the desired piece of genetic material
passes from the vector to the genetically engineered
species.4
B. Examples of How Genetic Engineering Is Carried Out
An example of genetic engineering by means of a vector is
the infection of certain plants by genetically engineered forms of
the bacterium Agrobacterium. Agrobacterium is a soil bacterium
that naturally attacks certain plants, infecting wounds and caus-
ing the development of swellings known as tumors. In 1977, it
was found that the tumors were due to the bacterium inserting
part of its genetic material into the host DNA. This means that if
foreign DNA is inserted into the DNA of Agrobacterium, the
Agrobacterium can in turn insert this foreign DNA into the genetic
material of any plants it subsequently attacks. This property can
be used by scientists to produce new crops.
Viruses can also be used as vectors in genetic engineering.
For example, retroviruses have been used in genetic engineering
research on humans. Retroviruses are good candidates for this
approach as they have millions of years of experience at inserting
their genetic material into that of a host. A number of diseases
are caused by mutations in genes expressed in bone marrow
cells-the cells that give rise to our blood cells. Retroviruses
have been used in attempts to insert a functional copy of the
faulty gene into these bone marrow cells. The aim is to ensure
that all the blood cells that descend from these bone marrow
cells are healthy.5
One problem with this approach, which limits the number
of diseases on which trials are being run, is that retroviruses only
3. See Michael Reiss, Biotechnology, in 1 ENCYCLOPEDIA OF APPLIED ETHICS
319, 321 (Ruth Chadwick ed., 1988).
4. See id.
5. See Kohnoske Mitani & C. Thomas Caskey, Delivering Therapeutic
Genes-Matching Approach and Application, 11 TRENDS IN BIOTECH. 162, 163-64
(1993).
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infect dividing cells. Many human diseases, for example those of
the nervous system, are not caused by mutations in dividing cells:
A second problem is that, as so often in genetic engineering,
there is no control presently available as to where the gene is
inserted in the human chromosomes. Instead, the retrovirus
inserts the desired gene more or less randomly.6 This has two
consequences. First, the new gene may not be as effective as
when it is located in its normal place. This is because genes often
work best only if they are situated close to certain other genes
which help turn them on and off. The second, and more dan-
gerous, possible consequence is that the new gene may, by mis-
take, be inserted into an important gene, for example tumor-
suppressor genes which help prevent cancers. Disruption of the
activity of a tumor-suppressor gene by the insertion of a new
gene through the activity of a retrovirus has been shown in
monkeys to lead on occasions to the development of cancer.7
For these reasons, researchers are experimenting with other
viruses. For example, adenoviruses are being used in attempts to
insert functional copies of the gene, which, in its faulty form,
causes cystic fibrosis in humans. Adenoviruses, unlike
retroviruses, do not integrate their genes into their host's DNA.
This has both advantages and disadvantages.' An obvious disad-
vantage follows from the fact that any descendants of the geneti-
cally engineered cells do not carry the functional cystic fibrosis
gene. This means that once the genetically engineered cells die,
the functional cystic fibrosis gene is lost with them. As a result,
this approach is only likely to be effective if people with cystic
fibrosis are treated with genetically engineered adenoviruses
every few months. On the other hand, there is less risk of the
virus inserting its genetic material into the host cells in such a
way as to disrupt normal functioning or even cause cancer.
9
One way of getting DNA into a new organism, without using
a vector, is simply to fire it in via a gun, i.e., biolistic (particle-
gun) delivery. The DNA is mixed with tiny metal particles, usu-
ally made of tungsten. These are then fired into the organism,
or a tissue culture of cells of the organism. The chief advantage
of this method is its simplicity, and it is widely used in the genetic
engineering of plants. One problem, not surprisingly, is the
damage that may be caused as a result of the firing process. A
6. See MICHAEL J. REIss & ROGER STRAUGHAN, IMPROVING NATURE? THE
SCIENCE AND ETHICS OF GENETIC ENGINEERING 41 (1996).
7. See id.
8. See Myra Stern & Eric W.F.W. Alton, Gene Therapy for Cystic Fibrosis, 45
BIOLOGIST 37, 38 (1993).
9. See id.
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more intractable problem is that only a small proportion of the
cells tend to take up the foreign DNA."°
A second way of getting DNA into a new organism is by
injecting it directly into the nucleus of an embryonic cell. This
approach is quite widely used in the genetic engineering of ani-
mals. This method ensures that at least some of the cells of the
organism take up the foreign DNA.'1
C. Two Fundamental Types of Genetic Engineering
A final principle of genetic engineering is that it can take
place in one of two ways-one that involves the genetic engineer-
ing of germ-line cells, the other the genetic engineering of
somatic cells. Germ-line cells are the cells found, in mammals, in
the ovaries of a female and the testes of a male and give rise,
respectively, to eggs and to sperm. Somatic cells are all the other
cells in the body.' 2
The importance of this distinction is that any genetic
changes to somatic cells cannot be passed on to future genera-
tions. Changes, on the other hand, to germ-line cells can indeed
be passed on to children and succeeding generations.13 For this
reason, changes to germ-line cells generally have wider ethical
implications than changes to somatic cells.
II. CYSTIC FIBROSIS
Cystic fibrosis is a common genetic disease in many coun-
tries, including the United States. Someone with cystic fibrosis
has severe breathing problems and typically suffers from lung
infections; their digestion is poor, they may develop diabetes,
and they produce abnormally salty sweat (not a problem in itself,
but used historically, before the advent of modern biotechnol-
ogy, as an indication that a baby had cystic fibrosis).1 4
It has long been known that cystic fibrosis is an example of
an autosomal recessive condition. By "autosomal" is meant that
the gene responsible is on neither the X- nor the Y-chromo-
somes, but on one of the other, non-sex, chromosomes.
15
10. See WILLIAM BAINS, BIOTECHNOLOGY FROM A TO Z 42 (1993).
11. See id. at 147-48.
12. For example, the cells of our digestive system, nervous system,
cardiovascular system, lungs, and skin are all somatic. See ROBERT F. WEAV-%ER &
PHILIP W. HENDRICK, GENETICS 320 (2d ed. 1992).
13. See id.
14. See Stem & Alton, supra note 8, at 37-38.
15. See generally ALAN E.H. EMERY & ROBERT F. MUELLER, ELEMENTS OF
MEDICAL GENETICS (8th ed. 1992).
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(Humans have 44 autosomal and two sex chromosomes, women
being XX and men XY.) By "recessive" is meant that an affected
person has two faulty versions of the gene. In the great majority
of cases this is simply because both the copy inherited from the
mother and the one from the father are faulty.' 6 People with
one normal and one abnormal form of the cystic fibrosis gene
are known as heterozygotes (the standard genetic term for an
organism with two different forms of a single gene). Because the
faulty copy is recessive, heterozygotes are perfectly normal and
have none of the symptoms of cystic fibrosis. However, if they
have children with another person who is heterozygous for the
gene, there is a one in four probability that any child they have
will have cystic fibrosis.'
7
The various symptoms of cystic fibrosis can be traced back to
a single consequence of the faulty gene-the excessive produc-
tion of abnormally thick, sticky mucus. In the lungs, this thick
mucus clogs up the delicate alveoli (air sacs) and smaller bron-
chioles. As a result, breathing is difficult and the person is prone
to lung infections. In the pancreas the large amounts of sticky
mucus block the exit for the various pancreatic enzymes that nor-
mally go to our small intestines and help digest our food.'" As a
result, a person with cystic fibrosis suffers from poor digestion as
the enzymes fail to reach the small intestine. In addition, these
pancreatic digestive enzymes-unable to reach the gut and
instead accumulating in the pancreas-may start to attack the
pancreas itself. As a consequence the pancreas may literally be
eaten away. As the pancreas produces the hormone insulin,
which regulates blood sugar levels, people with cystic fibrosis may
develop diabetes-as this results from insufficient production of
insulin. 9
In 1989, the defective gene responsible for cystic fibrosis was
finally isolated on the long arm of chromosome 7.20 This gene
codes for a protein which controls the movement of chloride
ions across cell membranes. The defective gene prevents the
movement of chloride ions out of cells. Normally water follows
these chloride ions and makes the mucus secreted by cells quite
runny. In the absence of these chloride ions, less water accompa-
nies the mucus which is consequently more sticky. This simple
16. See id at 2-3.
17. See id at 2-3, 42.
18. See Jane C. Davies et al., Prospects for Gene Therapy for Cystic Fibrosis, 4
MOLECULAR MED. TODAY 292 (1998).
19. See REiss & STRAUGHAN, supra note 6, at 203.
20. See Stern & Alton, supra note 8, at 37.
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fact is probably sufficient to cause all the problems associated
with cystic fibrosis.
21
The isolation of the gene responsible for cystic fibrosis has
opened up the reality of genetic screening. A simple test of a
person's saliva, costing about the price of a newspaper, allows
identification of carriers (people who have one healthy and one
faulty copy of the gene)-though only with about ninety percent
accuracy. 22 Suppose you have a close relative who has cystic
fibrosis, but you don't. There is a chance that you are a carrier.
You might choose to undergo screening, for example, if you are
about to start a family.
Suppose you and your partner both discover that you are
carriers, and the two of you are expecting a baby: there is a one
in four chance that the baby will have cystic fibrosis. Genetic
screening gives you the opportunity to use antenatal diagnosis to
see if the baby will have cystic fibrosis or not. Using amni-
ocentesis or chorionic villus sampling, a tiny sample of cells from
the developing fetus is taken. 23 The relevant gene is examined
in the laboratory and a diagnosis can be made. Three-quarters of
the time the news will be good: the baby won't have cystic fibro-
sis. However, on a quarter of the occasions, the news will be bad:
the baby will have cystic fibrosis.
At present the only option available to a couple in this posi-
tion is to decide whether to continue with the pregnancy or opt
for a termination. Many opt for a termination, a decision of
great personal and moral significance, particularly as most peo-
ple with cystic fibrosis live into adulthood.24 Gene therapy and
conventional treatment are beginning to open up new avenues
of treatment.
The problems that cystic fibrosis causes for the digestive sys-
tem can be controlled fairly well with drugs. However, the dam-
age to the lungs eventually proves fatal and few people with cystic
fibrosis live to be forty.25 Somatic gene therapy offers the hope
of halting, or at least slowing, the lung damage. The main steps
are as follows:
1. Obtain a healthy copy of the cystic fibrosis (CF) gene.
2. Insert the CF gene into the genetic material of a conve-
nient bacterium.
21. See Davies et al., supra note 18, at 292.
22. See REiss & STRAUGHAN, supra note 6, at 203.
23. Both amniocentesis and chorionic villus sampling carry a small risk,
on the order of 0.5 to 2 percent, of causing a miscarriage.
24. See REiss & STRAUGHAN, supra note 6, at 204.
25. See id.
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3. Allow the bacteria to reproduce many times.
4. Remove the healthy copies of the CF gene from the
bacteria.
5. Put these healthy CF genes into a vector (such as a
harmless virus).
6. Use this vector to carry the healthy CF genes to the
cells that line the lungs.
7. Here, the CF genes insert themselves into the DNA in
these cells.
8. The CF genes then make the missing protein.
9. The missing protein then moves to the membrane that
surrounds the cell.
10. Here it regulates the passage of chloride ions, allowing
the mucus produced by the cell to be its normal runny
consistency.
26
Three main vectors have been tried to allow step six to take
place. One approach is to use hollow membranous spheres
called liposomes. The advantage of liposomes is that they easily
fuse with the membranes that surround cells, thus releasing their
contents into the cytoplasm of the cells. The disadvantage is that
most of the genes carried in this way don't end up inserting
themselves into the cell's DNA. A second approach is to use a
retrovirus. Retroviruses are viruses which are very efficient at
inserting genes into the cell's DNA. There is, however, a worry,
that there may be an increased risk of this damaging the normal
controls on cell growth. In the worst case this could conceivably
trigger a cancer. The third approach is to use a cold virus. Cold
viruses, of course, are rather good at carrying genes into lung
cells. Unfortunately, they can also cause inflammation of the
lungs, the last thing someone with damaged lungs wants.
2 7
Early indications are that somatic gene therapy should be a
valuable treatment, though perhaps its effects will be less spectac-
ular than had been widely hoped. One encouraging finding is
that it seems that only ten percent of the cells lining the lungs
need to have the missing proteins in their membranes replaced
for the lung to function normally.
28
Before we leave cystic fibrosis, we should note that even with-
out gene therapy tremendous advances have been made in the
treatment of cystic fibrosis. Average life expectancy for people
with cystic fibrosis has increased dramatically in recent years-in
26. See Davies et al., supra note 18, at 293-96.
27. See Mitani & Caskey, supra note 5, at 162-65.
28. See Fiona Watson, Human Gene Therapy-Progress on All Fronts, 11
TRENDS IN BIOTECH. 114, 116 (1993).
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western countries from just one year in 1960 to five years in 1970
to ten years in 1980 to almost twenty years in 1990 and to around
twenty-five years in 1995.29 These improvements have come
about partly through aggressive antibiotic regimes used to fight
off lung infections, and partly through intensive, daily physio-
therapy which is time consuming and can be painful.
New advances continue to be made. In 1993, Genentech
published the results of clinical trials on a new drug called
pulmozyme. This reduces lung infection and shortness of
breath.3 ° In 1995, a Cleveland team published the results of a
four-year clinical trial of a new drug called ibuprofen. They
found that it slows lung deterioration by almost ninety percent in
children who start taking it before their teens.3 '
Advances, such as these, in conventional medicine do not of
course eliminate the potential of gene therapy. However, they
remind us that gene therapy may not be the only way of treating
even genetic diseases such as cystic fibrosis.32 In addition, the
present work with liposomes and viruses as vectors should not be
seen as a permanent solution to the problems of cystic fibrosis.
Because the cells lining the lungs are shed quite rapidly,
repeated gene therapy will probably be needed. Nevertheless,
there is a real chance that gene therapy may come to play a sig-
nificant part in the treatment of cystic fibrosis, allowing many
tens of thousands of people to enjoy a far better quality of life.
III. SoMATic GENE THERAPY FOR OTHER DISEASES
I have concentrated so far on cystic fibrosis because of its
widespread occurrence and because of the potential genetic
engineering has to help people with this condition. However,
what may have been the first successful attempts to genetically
engineer humans were initially carried out in 1990, three years
before trials began on cystic fibrosis.34
These attempts involved patients with a very rare disorder
known as severe combined immune deficiency (SCID). In some-
one with SCID, the immune system doesn't work. As a result the
person is highly susceptible to infections. Children with SCID
are sometimes known as bubble babies because, until recently,
29. See REISs & STRAUGHAN, supra note 6, at 206.
30. See Stephen M. Edgington, Nuclease Therapeutics in the Clinic, 11 BIO/
TECH. 580, 580-82 (1993).
31. See Cystic Fibrosis Drug, NEw SCIENTIsT, Apr. 8, 1995, at 11.
32. See REiss & STRAUGHAN, supra note 6, at 206.
33. See id.
34. See W. French Anderson, Human Gene Therapy, 392 NATURE 25, 25-30
(1998).
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almost the only way to allow them to live more than a few years
was to isolate them in plastic bubbles. These bubbles protect the
children from harmful germs but also, poignantly, cut them off
from all social contact. In any event, at best the bubbles prolong
life by only a few years."
SCID can have a number of causes. Probably the single most
common one is an inherited deficiency in a single enzyme-
adenosine deaminase (ADA). 6 The first person with SCID to be
treated with gene therapy was a four year-old girl named
Ashanthi De Silva. She was unable to produce ADA, and in 1990
some of her white blood cells were removed and functioning ver-
sions of the ADA gene were introduced into them using a virus as
a vector.3 7 The improvement in her condition was remarkable.
Soon she was living a comparatively normal life, attending a typi-
cal school and so on. She was no more likely to catch infections
than her classmates and, on one notable occasion, when she and
all her family caught the flu, she was the first to recover. At pres-
ent she gets regular transfusions (every few months) of geneti-
cally engineered white blood cells, as the white blood cells live
less than a year."8 However, in addition to being treated in this
way, she continues to receive conventional treatment and it is
possible that this, rather than genetic engineering, is what has
been of therapeutic value.
It may eventually be possible to modify so-called stem cells.
Stem cells are immortal; they reside in the bone marrow and give
rise to the different types of blood cells.3" At present, however,
identifying and purifying stem cells is proving difficult. If they
can be genetically engineered they hold out the hope of a com-
plete cure for SCID.
To date, many hundreds of trials for somatic gene therapy
have been approved, mostly in the United States. In addition to
trials on people with cystic fibrosis and SCID, somatic gene ther-
apy is being tried for a number of other conditions including
familial hypercholesterolemia, Duchenne muscular dystrophy,
hemophilia, 1-thalassemia, and cancers." In some cases, the





39. See BAINS, supra note 10, at 300-01.
40. See Betty Dodet, Commercial Prospects for Gene Therapy-A Company
Survey, 11 TRENDS IN BIOTECH. 182, 183 (1993);Jeffrey L. Fox, NIHRACApproves
11 Gene Therapy Protocols, 11 BIo/TECH. 780 (1993); Watson, supra note 28, at
114-16.
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results have been very encouraging, though progress has been
slower than hoped4" and has led to some spectacular falls (often
in the wake of spectacular rises) in share prices for biotechnology
companies.
V. THE SCOPE OF SOMATIC GENE THERAPY
It is easy, given the initial successes of somatic gene therapy,
to get carried away, hoping that it will soon be a cure for all our
problems. It is important, however, to be clear about the poten-
tial scope of gene therapy. For a start, it should be realized that
some human diseases caused by faulty genes can already be
treated quite effectively by conventional means. For example,
every baby born in most western countries is tested for the
genetic disease phenylketonuria, though the baby's parents prob-
ably aren't aware of this. The reason is that, provided action is
taken soon after birth, the harmful consequences of the condi-
tion can be prevented.42
A. Treatment of Phenylketonuria Does Not Require
Genetic Engineering
Phenylketonuria is a condition which, if untreated, leads to
the person being severely mentally retarded. Affected individu-
als often have convulsions and, in the past, were frequently insti-
tutionalized. Since the 1950s, though, it has been realized that
the condition can be entirely prevented.4" If children with the
faulty gene that causes phenylketonuria are given a diet that has
only small amounts of the amino acid phenylalanine, they grow
up healthy and normal. This is because they lack a particular
enzyme which converts phenylalanine into another amino acid,
tyrosine. It is the build-up in the levels of phenylalanine that
causes the problems. Keeping the levels of phenylalanine in the
diet low therefore prevents the harmful consequences of the con-
dition.44 Such a diet is extremely boring for children and quite
expensive but these are small prices to pay in light of the benefits
the diet brings.
41. See Anthony Meager & Elwyn Griffiths, Human Somatic Gene Therapy,
12 TRENDS IN BIOTECH. 108 (1994); DavidJ. Weatherall, The Thalassaemias, 314
BRITISH MED. J. 1675 (1997).
42. See EMERY & MUELLER, supra note 15, at 69-73; see also PHILIP KITCHER,
THE LIVES TO COME: THE GENETIC REVOLUTION AND HUMAN POSSIBILITIES
(1996).
43. See EMERY & MUELLER, supra note 15, at 69-73.
44. See id.
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Phenylketonuria illustrates a most important truth about
human development: both genes and the environment play
essential parts. True, phenylketonuria is a genetic disease in the
sense that it is the result of a faulty gene. But the extent to which
the disease manifests itself depends on the environment. A nor-
mal diet (i.e., normal environment) and the person is severely
affected; a special diet (i.e., a different environment) and the
person is unaffected. To describe phenylketonuria, or any other
condition, as a "genetic disease" is, at best, a convenient short-
hand. Both genes and the environment are involved in the man-
ifestation of any trait. Shorthand is useful so long as one doesn't
forget what it stands for.4 5
So, changing the environment can prevent some genetic dis-
eases. In essence, changing the environment is how all conven-
tional medicine works. Consider, for instance, juvenile-onset
diabetes. Again, the disease is "genetic" yet its symptoms can
largely-though not entirely-be prevented by regular injections
with insulin. This insulin can be obtained from pigs or cows, or
it can be produced by bacteria that have been genetically engi-
neered to produce human insulin.4 6 Of course, it may turn out
to be the case that the best results will come from genetically
engineering humans so that their pancreases produce their own
insulin twenty-four hours a day. However, the fact that countless
diabetics have been able to lead relatively normal lives thanks to
insulin injections, instead of dying painfully in childhood or ado-
lescence, shows how both genes and the environment play a vital
role in development.
B. Changing Single Genes Is Rarely Enough to Prevent or
Cure Disease
A second reason why we should not see gene therapy as the
likely solution to all medical problems also relates to the roles
played by genes and the environment. Frequent announcements
in the press that the gene for breast cancer, cancer of the colon,
Alzheimer's disease, or schizophrenia has been identified may
appear to offer the hope for a cure. The reality, though, is often
far from this.
First, knowing what causes a condition may be a valuable
step in preventing it, but it is most definitely not the same thing.
You may be unable to speak Russian or play the trumpet, and, if
this is the case, you probably know why you can't. But knowing
this is no more than the first step in helping you achieve these
45. See Russ & STRAuGHAN, supra note 6, at 209.
46. See id at 209-10.
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ends. In the same way, knowing which of the many human genes
causes a disease is a very long way from treating, curing, or
preventing it. Initially, it simply offers the possibility of genetic
screening.
Second, diseases such as cystic fibrosis, phenylketonuria, and
sickle-cell disease are the exception, not the rule. These condi-
tions are caused by inborn errors in single genes. However, only
around two percent of our total disease load is due to errors in
single genes, such as these, or to chromosome mutations such as
those leading to Down's syndrome and Turner's syndrome,
where the person is born with an extra chromosome.47 The
great majority, ninety-eight percent, of human disease is not like
this. For a start, most human diseases have a strong environmen-
tal component, so that genetic defects merely predispose the per-
son to develop the condition. Then, the genetic component is
the result of many genes.48
A condition affected by many genes is called a "polygenic"
condition or trait. Human skin color, for instance, is a polygenic
trait. In school, students are taught a very simplified, and some-
what misleading, version of human genetics. For example,
human eye color is generally taught as being determined by just
a single gene. In reality, though, eye color is determined by sev-
eral genes. Indeed, the vast majority of human traits are deter-
mined polygenically.49
A final point is that we are only just beginning to appreciate
the extent to which the human body, and mind, can overcome
genetic handicaps. Particular genetic mutations certainly
increase the risk of an individual developing certain cancers or
heart disease. Similarly, there may well be genetic mutations
which increase one's risk of developing schizophrenia or depres-
sion. However, this is very different from saying that there is "a
gene for breast cancer" or "a gene for schizophrenia." In the
case of breast cancer, early indications are that while a mutation
in the BrCA1 gene greatly increases a woman's chance of devel-
oping breast cancer, it is still the case that at least fifteen percent
of women with this mutation do not go on to develop breast can-
cer. Further, it is probable that many women with a history of
breast cancer in their family do not have a mutation in this
47. SeeJohn Horgan, Eugenics Revisited, Sci. Am., June 1994, at 92.
48. See Richard Strohman, Epigenesis the Missing Beat in Biotechnology, 12
BIo/TECH. 156 (1994); see also Horgan, supra note 47, at 92.
49. See generally CURT STERN, PRINCIPLES OF HUMAN GENETICS 443-67 (3d
ed. 1973) (discussing mechanisms and scope of polygenic inheritance).
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gene.5 ° In the case of the "colon gene," a mutation in the gene
accounts for only ten percent of all colon cancers, while some-
one with an altered form of the gene has a thirty percent chance
of never developing colon cancer.51
The fact that most important human diseases have a heavy
environmental component, are almost always affected by several
genes, rather than just one, and are frequently modulated in
their severity by the actions of the human body means that the
scope for gene therapy is likely to be more limited than many
suspect.
So far I have confined myself to what we may term "real
human diseases." But what of gene therapy to affect traits such as
intelligence, beauty, criminality, and sexual preference. Will this
ever be practicable?
Although there are frequently reports in the popular press
of "a gene for homosexuality" or "a gene for criminality" our dis-
cussion of the complexity of human disease should caution us
against such simplistic notions. True, it is the case, as shown by
twin studies, cross-fostering, and other evidence, that much
human behavior has a genetic component to it. However,
attempts to find genes for homosexuality, intelligence, beauty, or
criminality are, at best, the first steps to understanding the rich
and complex ways in which we behave. At worst, they are mis-
guided attempts to stigmatize certain members of society. Part of
the very essence of our being human is that we, above all the
other organisms with which we share this planet, have the poten-
tial to transcend much of our biological heritage. We are more-
far, far more-than our genes.52
V. THE ETHICAL SIGNIFICANCE OF SOMATIC GENE THERAPY
What new ethical issues are raised by somatic gene therapy?
The short answer, when we are talking about real human dis-
50. See R. GRANT STEEN, DNA AND DESTINY. NATURE AND NURTURE IN
HuMAN BEHAVIOR (1996); Phyllidia Brown, Breast Cancer 'Too Complex'for Gene
Test, NEW SCIENTIST, Dec. 10, 1994, at 4.
51. See Susan Katz Miller, 'Colon Gene' Rounds Off A Brilliant Year, NEW
SCIErIST, Dec. 11, 1993, at 4.
52. This point is argued in detail in STEVEN ROSE ET AL., NOT IN OUR
GENES: BIOLOGY, IDEOLOGY AND HUMAN NATURE (1984), and in RICHARD C.
LEWONTIN, BIOLOGY AS IDEOLOG. THE DOCTRINE OF DNA (1992). See also
MICHAEL J.A. HowE, IQ IN QUESTION: THE TRUTH ABOUT INTELLIGENCE (1997);
JANET SAYERS, BIOLOGICAL POLITICS: FEMINIST AND ANTI-FEMINIST PERSPECTIVES
(1982); Special Issue: Intelligence and Social Policy, 24 INTELLIGENCE 1 (Linda S.
Gottfredson ed., 1997); Udo Schfiklenk et al., The Ethics of Genetic Research on
Sexual Orientation, HASTINGS CENTER REP., July-Aug. 1997, at 6.
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eases, is probably none. Of course, somatic gene therapy is still a
very new technique, and mostly at the research rather than the
clinical stage. However, there is considerable agreement about
how medical research and innovative practice should be regu-
lated in the light of ethical considerations. 3 There is little doubt
that ethical considerations have so far been applied to somatic
gene therapy even more stringently than to conventional
medicine.
In January 1992, in the United Kingdom, the Clothier Com-
mittee produced its report on the ethics of somatic gene therapy.
After carefully reviewing such considerations as the likely success
of the procedure, consent, and confidentiality, the Clothier
Committee's decision was that:
We conclude that the development and introduction of
safe and effective means of somatic cell gene modification,
directed to alleviating disease in individual patients, is a
proper goal for medical science. Somatic cell gene therapy
should be regarded, at first, as research involving human
subjects and we recommend that its use be conditional
upon scientific, medical and ethical review. Although the
prospect of this new therapy heightens the familiar ethical
concerns which attend the introduction of any new treat-
ment, we conclude that it poses no new ethical problems.54
Although the United Kingdom government waited over a
year to respond, it eventually accepted this recommendation.
Other countries too, including, of course, the United States, have
permitted somatic gene therapy. Because somatic gene therapy
typically involves giving a person healthy DNA to override the
effects of their own malfunctioning DNA, it has been pointed out
that this is not very different from giving a person a blood trans-
fusion or organ transplant. Of course, some individuals may
choose not to have a transfusion or transplant, but very few peo-
ple suggest forbidding them entirely.
It is also the case that somatic gene therapy has the potential
to reduce the number of ethically problematic decisions. For
example, at present the only "solution" offered to a woman who
53. See TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF
BIOMEDICAL ETHICS (4th ed. 1994); BIOETHICS: BASIC WRITINGS ON THE KEY
ETHICAL QUESTIONS THAT SURROUND THE MAJOR, MODERN BIOLOGICAL
POSSIBILrlES AND PROBLEMS (Thomas A. Shannon ed., 4th ed. 1993); BIRTH TO
DEATH: SCIENCE AND BIOETHICS (David C. Thomasma & Thomasine Kushner
eds., 1996); LAN KENNEDY, TREAT ME RIGHT: ESSAYS IN MEDICAL LAW AND ETHICS
(1988).
54. CLOTHIER COMMITTEE, REPORT OF THE COMMITTEE ON THE ETHICS OF
GENE THERAPY 17 (1992).
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is carrying a fetus identified as having a serious genetic disorder
such as cystic fibrosis or muscular dystrophy is the possibility of
an abortion. Somatic gene therapy may be able to offer a more
positive way forward.
However, somatic gene therapy may, in time, raise new ethi-
cal issues. Suppose, despite what we have said about the com-
plexities of human behavior, it does eventually transpire that
somatic gene therapy could reduce the likelihood of someone
being violently aggressive or of being sexually attracted to others
of the same sex. What then? The simple answer is to throw one's
hands up in horror and agree that such "treatments" should be
outlawed. However, one problem with this response is that most
countries already spend a lot of time and effort trying to get peo-
ple who have been convicted of violent crimes to be less likely to
commit these again. They may attend education programs or
receive state-funded psychotherapy, for instance, in attempts to
achieve these aims. Similarly, some psychiatrists and counselors
are still prepared to work with homosexuals to help them change
their sexual orientation.
These two examples (violent behavior and homosexuality)
highlight two related issues. The first has to do with the social
construction of disease. It is easy to assume that diseases are
fixed, objective realities. A different approach is to accept that a
disease is, in a sense, a relationship a person has with society. Is
being four feet tall a disease? The answer tells us more about a
society than it does about-an individual of this height. Some con-
ditions are relatively unproblematic in their definition as a dis-
ease. For instance, Lesch-Nyhan disease is characterized by
severe mental retardation, uncontrolled movements (spasticity)
and self-mutilation. 5 No cure is at present available and the per-
son dies, early in life, after what most people would consider an
unpleasant existence. It is the existence of conditions such as
this that have even led to claims in the courts of wrongful life or
wrongful birth where a sufferer, or someone acting on their
behalf, sues either their parent(s) or doctor(s) on the grounds
that it would have been better for them never to have been
born.5 6 However, years of campaigning by activists for people
with disabilities have shown us the extent to which many diseases
or disabilities are as much a reflection of the society in which the
55. See EMERY & MUELLER, supra note 15, at 78.
56. See Turpin v. Sortini, 643 P.2d 954 (Cal. 1982) (denying recovery for
general damages in suit brought on behalf of child alleging wrongful life);
Gleitman v. Cosgrove, 227 A.2d 689 (N.J. 1967) (same).
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person lives as they are the product of the genes and internal
environment of that person.
The second issue has to do with consent. It is one thing for
a person convicted of a violent crime to give their informed con-
sent to receive psychotherapy or some other treatment aimed at
changing their behavior-though even these treatments are, of
course, open to abuse.57 It would be quite another for a parent
to decide, on a fetus' or baby's behalf, to let it receive somatic
gene therapy to make it less aggressive.
In an attempt to set limits on the operation of somatic gene
therapy, the Clothier Committee concluded that, "In the present
state of knowledge any attempt by gene modification to change
human traits not associated with disease would not be accepta-
ble."58 Similarly, the arguments of members of a number of the
world's major religions at the 1992 conference on "Genetics,
Religion and Ethics" held in Houston, Texas are fairly repre-
sented by the view of George Pazin, a member of the Orthodox
Church and professor at the University of Pittsburgh School of
Medicine, who stated "I am all in favor of repairing God's crea-
tion with the genetic tools that we have discovered, but I shudder
to think of our trying to improve upon the creation."59 At the
present time it may be difficult to be more precise than these last
two quotes. However, it is worth noting that several countries
officially permit abortions only on health grounds yet, in prac-
tice, offer abortion on demand. By analogy, should the use of
somatic gene therapy ever become widespread it may be difficult
to prevent it being used for cosmetic purposes, in much the same
way that plastic surgery can be used both for life-saving and for
trivial purposes.
VI. THE ETHICAL SIGNIFICANCE OF GERM-LINE THERAPY
The idea of genetic alterations to the human germ-line (so
that succeeding generations are affected, rather than just the
individual concerned) has been rejected by a number of reli-
gious writers and organizations,6 ° as it has by many secular writ-
57. See generally JEREMY HOLMES & RICHARD LINDLEY, THE VALUES OF
PSYCHOTHERAPY (1989).
58. CLOTHIER COMMITTEE, supra note 54, at 22.
59. J. ROBERT NELSON, ON THE NEW FRONTIERS OF GENETICS AND RELIGION
151 (1994).
60. In 1983, fifty-eight scientific and religious leaders signed a statement
calling for the banning of all germ-line research in humans. See Stephen
Budiansky, Anatomy of a Pressure Group, 309 NATURE 301, 302 (1984); see also
SUBUNIT ON CHURCH AND SOCIETY, WORLD COUNCIL OF CHURCHES,
BIOTECHNOLOGY. ITS CHALLENGES TO THE CHURCHES AND THE WORLD (1989); H.
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ers and organizations.61 The main arguments against human
germ-line therapy are as follows:
1. It is too risky.
2. It is unnecessary.
3. It is wrong.
However, others, including a number of distinguished moral
philosophers and some theologians, have argued that the time
may come when germ-line therapy is permissible, even highly
desirable.6" Some people believe that time is fast approaching.
A. Is Germ-Line Therapy Too Risky?
At the moment it is generally acknowledged that human
germ-line therapy is too risky. Researchers cannot, at present,
control precisely where new genes are inserted.63 This raises the
not insignificant danger that the inserted gene might damage an
existing gene, which could lead to diseases, including cancers.
We can note, in passing, that the existence, despite these
problems, of germ-line therapy (perhaps better referred to as
"germ-line manipulation") in animals (i.e.; non-human animals)
illustrates the distinction between what is generally deemed
acceptable for animals and for humans. Such germ-line manipu-
lation is being used increasingly in agriculture and in
medicine.64
However, although human germ-line therapy may currently
be too risky, it is difficult to imagine that this will continue to be
the case indefinitely. It seems extremely likely that scientists will
Jochemsen, Medical Genetics: Its Presuppositions, Possibilities and Problems, 8 ETHICS
& MED. 18 (1992).
61. See, e.g., BRITISH MEDICAL ASSOCIATION, OUR GENETIC FUTURE: THE
SCIENCE AND ETHICS OF GENETIC TECHNOLOGY (1992); DAVID SUZUKI & PETER
KNUDTSON, GENETHICS: THE CLASH BETWEEN THE NEW GENETICS AND HUMAN
VALUES (1989); see also GROUP OF ADVISORS ON THE ETHICAL IMPLICATIONS OF
BIOTECHNOLOGY, EUROPEAN COMMISSION, 1994 REPORT (1996). A number of
feminist authors, in particular, have been extremely suspicious about the
genetic engineering of humans, suspecting that women are being used as
guinea pigs or to produce "perfect babies." See RoBYN ROWLAND, LIVING
LABORATORIES: WOMEN AND REPRODUCTIVE TECHNOLOGY (1992); PATRICIA
SPALLONE, GENERATION GAMES: GENETIC ENGINEERING AND THE FUTURE FOR OUR
LIVES (1992).
62. See generally CELIA DEANE-DRUMMOND, THEOLOGY AND BIOTECHNOLOGY
(1997); JONATHAN GLOVER, WHAT SORT OF PEOPLE SHOULD THERE BE? (1984);
JOHN HARRIS, WONDERWOMAN AND SUPERMAN: THE ETHICS OF HUMAN
BIOTECHNOLOGY (1992); TED PETERS, PLAYING GOD: GENETIC DETERMINISM AND
HUMAN FREEDOM (1997); Mary Warnock, Ethical Challenges in Embryo
Manipulation, 304 BRITISH MED. J. 1045 (1992).
63. See generally CLOTHIER COMMITTEE, supra note 54.
64. See REISS, supra note 3, at 325-30.
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develop methods of targeting the insertion of new genes with suf-
ficient precision to avoid the problems that presently attend such
procedures. Nor need these new methods require much, possi-
bly any, experimentation on human embryos. A great deal, per-
haps all, of the information could be obtained through the
genetic engineering of farm animals.
Further, we should realize that although germ-line therapy is
typically assumed to be irreversible, it is more likely, if we ever get
to the point where its use is routine, that it will normally be
reversible. There is no reason to suppose that if something went
wrong with the results of germ-line therapy, this wrong would
necessarily be visited on a person's descendants in perpetuity.
The same techniques that would permit targeted germ-line ther-
apy should permit its reversal.
B. Is Germ-Line Therapy Unnecessary?
It is no easy matter to demonstrate that something is "neces-
sary." Value judgments are involved, so that there may be genu-
ine controversy about whether something is needed. Is the
motor car necessary? Or elephants? Or free trade? It is likely
that most improvements that might result from germ-line ther-
apy could also be effected by somatic gene therapy or conven-
tional medicine. Cystic fibrosis and diabetes are cases in point.
However, it may prove to be the case that germ-line therapy
allows such conditions to be treated better. It is possible that
germ-line therapy might be able to produce certain benefits that
could not be realized by any other technique. No doubt the
human race would be able to get on without germ-line therapy,
and one may question whether it would do much to increase the
sum of human happiness. Nevertheless, at some point it may
convincingly be argued that germ-line therapy is necessary for
some individuals.
C. Is Germ-Line Therapy Wrong?
Making the assumption, then, that one day germ-line ther-
apy will both be relatively safe and deemed necessary, in the
sense that it can bring benefits that other approaches cannot, is it
right or is it wrong?
It is sometimes argued that germ-line therapy will decrease
the amount of genetic variation among people and that this is
not a good thing, since evolution needs genetic variation.65
There are several things that are dubious about this objection.
65. See generally SuzuKi & KNUDTSON, supra note 61.
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First, empirically, it is difficult to imagine in the foreseeable
future that germ-line therapy will significantly decrease the
amount of useful human variation among people. Second, it is
possible that germ-line therapy may one day lead to even more
genetic variation-as some parents opt for certain genes in their
children and other parents for other genes. Third, the argument
that evolution needs genetic variation is difficult to sustain faced
with someone suffering from a disease that is largely the result of
a genetic mutation. The argument relies on possible, very distant
advantages for groups of people being sufficient to override the
more immediate, clear disadvantages for individuals.
Then some people have expressed the fear that germ-line
therapy might be used by dictators to produce only certain types
of people. Perhaps the major problem with this objection is that
it assumes too much of genetic engineering. As I argued in the
context of somatic gene therapy, it is easy to overstate the extent
to which humans are controlled by their genes. Dictators have
had, have, and will have far more effective ways of controlling
people.
A more likely problem is that germ-line therapy will be per-
mitted before people have grown sufficiently accustomed to the
idea. The pace of technological change is so fast nowadays that
some people end up feeling bewildered by new possibilities. It is
worth recalling that people in many countries have grown com-
fortable with such practices as organ transplants and in vitro fer-
tilization, though such procedures gave rise in the aftermath of
their initial development to considerable ethical debate (not all
of which, of course, has died away-in Japan transplants remain
unacceptable, as in vitro fertilization is to many Roman
Catholics). Similarly, perhaps human germ-line therapy will
become broadly acceptable. The theologian, Ian Barbour, has
argued that it is important that sufficient time is allowed before
germ-line therapy on humans is permitted, both to ascertain, so
far as is possible, that the procedure is safe and so that people
may feel comfortable with the idea:
[I] would approve germ-line therapy only under three con-
ditions. First, extensive studies of human somatic-cell thera-
pies similar to the proposed germ-line therapy must have
been conducted over a period of many years to acquire
data on the indirect effects of the genetic changes. Sec-
ondly, the effects of similar germ-line therapy in animals
must have been followed over a period of several genera-
tions to ensure the reliability and long-term safety of the
techniques used. Third, widespread public approval must
have been secured, since the therapy will affect unborn
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generations who cannot themselves give informed consent
to treatment.
66
A frequently expressed worry about germ-line therapy is the
extent to which future generations will be affected. Again, it is
possible that this fear may be an exaggerated one. As we have
said, we can overestimate the importance of our genetic make-
up. Then there is the point that people already have and will
continue to have a tremendous influence over future generations
through everything from child-rearing patterns and family plan-
ning to books and pollution. The philosophers Robert Nozick,6 7
Jonathan Glover,6 8 and John Harris6 9 have been quite bullish
about germ-line therapy. Indeed, Nozick, back in 1974, intro-
duced the notion of a 'genetic supermarket' at which parents,
rather than the state, could choose the genetic make-up of their
children. Harris has even argued that we may have a duty to
carry out germ-line therapy:
We must not act positively so as to cause harm to those who
come after us, but we must also not fail to remove dangers
which, if left in place, will cause harm to future people.
Thought of in this light, there is a clear dilemma about
genetic engineering. On the one hand we must not make
changes to the genetic structure of persons which will
adversely affect their descendants. On the other hand we
must not fail to remove genetic damage which we could
remove and which, if left in place, will cause harm to
future people.
70
There remains the worry, though, born of long experience
of slippery slopes, that the road to hell is paved with good inten-
tions. Despite the difficulties, which I reviewed earlier, of distin-
guishing in all cases genetic engineering to correct faults (such
as cystic fibrosis, hemophilia, or cancers) from genetic engineer-
ing to enhance traits (such as intelligence, creativity, athletic
prowess, or musical ability), the best way forward may be to ban
germ-line therapy intended only to enhance traits, at least until
many years of informed debate have taken place.
66. IAN G. BARBOUR, 2 ETHICS IN AN AGE OF TECHNOLOGY: THE GIFFORD
LECTURES 1989-91 197 (1992).
67. See ROBERT NoZICK, ANARCHY, STATE, AND UTOPIA (1974).
68. See GLOVER, supra note 62.
69. See HARRIS, supra note 62; see alsoJohn Harris, Biotechnology, Friend or
Foe? Ethics and Controls, in ETHICS AND BIOTECHNOLOGY 216 (Anthony Dyson &
John Harris eds., 1994).
70. HARRIS, supra note 62, at 178.
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The idea that it is useful to distinguish between genetic engi-
neering to treat disease and genetic engineering to enhance
traits appeals to some theologians who have argued that genetic
engineering to treat disease may be seen as part of the redemp-
tive activity of humans.7 At the same time, it is worth noting the
words ofJ. Robert Nelson, senior research fellow of The Institute
of Religion, Texas Medical Center and adjunct professor of med-
ical ethics at Baylor College of Medicine: "The prospect of over-
coming and even eliminating from the germ-line certain types of
human suffering is, like all other eschatologies, both appealing
and frightening.
7 2
John Habgood, the former Archbishop of York, has cau-
tioned against using genetic engineering to improve people. In
a talk given in 1995 he concluded:
So, six rules in a sentence. First, human beings are more
than their genes. Genes are only a set of instructions. We
are more than a set of instructions. Second rule: remem-
ber the valuable diversity of human nature. Third rule:
look for justice in the dealings of human beings with one
another and for fairness in the use of resources. Fourth
rule: respect privacy and autonomy. Fifth rule: accept the
presumption that diseases should be cured when it is possi-
ble to do so. And sixth rule: be very suspicious about
improving human nature; and be even more suspicious of
those who think they know what improvements ought to be
made.7 3
Nor is it only religious leaders who have warned of the dan-
gers of presuming to improve human nature or enhance human
capabilities. Jonathan Glover quotes the philosopher John
Mackie who once argued, against Glover's optimism about germ-
line therapy, that "if the Victorians had been able to use genetic
engineering, they would have aimed to make us more pious and
patriotic."
74
A related difficulty is that if we ever did succeed, through
either somatic cell or germ-line therapy, in enhancing such traits
as intelligence, memory, or altruism, there might be unforeseen
consequences. There exists a genetically engineered strain of
71. See generally RONALD COLE-TURNER, THE NEW GENESIS: THEOLOGY AND
THE GENETIC REVOLUTION (1993).
72. NELSON, supra note 59, at 164.
73. John Habgood, Heslington Lecture at the University of New York
(Feb. 1, 1995) (Transcript on file with the Notre Dame Journal of Law, Ethics &
Public Policy).
74. GLOVER, supra note 62, at 149.
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the fruit fly, Drosophila which learns ten times faster than the nor-
mal strain.75 At first sight the application of this technology to
humans sounds marvelous. Imagine learning ten times faster;
think of all the benefits it could bring. However, there may be
costs. Improved learning implies improved memory and if you
have a far superior memory you will forget far less. Most of us
have experienced unpleasant happenings which we are only too
grateful to forget. Further, there is some anecdotal evidence to
suggest that the handful of people who have total recall or per-
fect photographic memories find life difficult. For a start, they
don't always find it easy to know what day, month, or even year it
is. If you have a perfect memory, events a year ago may be almost
as fresh in your mind as events five minutes ago. This can lead to
confusion and can make social relationships difficult.
Finally, it might be the case that genetic engineering would
require parents to choose which traits they would like enhanced
in their children. It may, for example, prove impossible simulta-
neously to enhance a child's -ability to learn mathematics, paint,
show great empathy, and play a musical instrument. It can be
argued that genetic engineering to enhance human traits dimin-
ishes the autonomy of the person concerned-i.e., the geneti-
cally engineered child that results. On a more practical level,
one can imagine arguments between genetically engineered chil-
dren and their parents, with great unhappiness sometimes result-
ing: "We didn't pay for you to be musically gifted just to have you
spend all your time playing baseball" or "We didn't pay for you to
be an outstanding baseball player just to have you spend all your
time in a rock band."
Nevertheless, suppose that one day it really does become
possible safely to improve everyone's IQ by some twenty to forty
points through germ-line modification. Imagine further that this
procedure especially benefits those who would otherwise have an
IQ of below one hundred (in other words, it decreases the vari-
ance in IQ scores rather than increasing it) and that the proce-
dure can be carried out much more effectively and-cheaply than
via other routes (e.g. somatic gene modification, psychosurgery,
or extra education). My own belief is that it would prove difficult
to argue that such a procedure should be made illegal. It is more
likely that we would be discussing whether it should (like educa-
tion in general) be mandatory or (like school education) be
optional.
75. Peter Aldhous, Fruit Flies Achieve Total Recall, NEW SCIENTIST, Apr. 29,
1995, at 18.
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VII. MAKING ETHICAL DECISIONS
It may seem somewhat surprising only now in this article to
have a section on "Making Ethical Decisions," but there is a logic
to this. While the traditional approach in the West to making
ethical decisions historically has been to argue from general prin-
ciples to particular cases, ever since Carol Gilligan's classic book,
In a Different Voice,7 6 the value of arguing rather from particular
cases to general principles has increasingly been recognized.7 7
One reason for such an approach is that, without exaggerat-
ing too much, it can be asserted that Western moral philosophy
is currently, and has been for over a hundred years, in a state of
intellectual crisis. 78 The most obvious manifestation of this crisis
is the fact that there still exists no accepted framework within
which ethical decisions can be made. Quite the opposite: there
exist a number of competing and mutually incompatible
frameworks. The best known of these are the consequentialist
and the non-consequentialist ones. Consequentialists hold that,
to decide whether an action would be right or wrong, it is suffi-
cient to look at what its consequences would be, whereas non-
consequentialists hold that this is inadequate.79
My own view is that whether or not consequentialism in gen-
eral is sufficient as an ethical system, it is difficult to sustain non-
consequentialist objections to the genetic engineering of
humans. Suppose, for example, person A argues that it is intrinsi-
cally wrong (i.e., wrong whatever the consequences) to carry out
germ-line modification on humans. That means that even if it
could be shown that the relief of person B's suffering or the
advancement of person C's autonomy or the promotion of jus-
tice between persons D, E,... Z could only be achieved through
76. CAROL GILLIGAN, IN A DIFFERENT VOICE: PSYCHOLOGICAL THEORY AND
WOMEN'S DEVELOPMENT (1982).
77. See generallyJean Grimshaw, The Idea of a Female Ethic, in A COMPANION
TO ETHICS 491, 494-95 (Peter Singer ed., 1991).
78. See, e.g., ANNE MACLEAN, THE ELIMINATION OF MORALITY- REFLECTIONS
ON UTILITARIANISM AND BIOETHICS (1993); BERNARD WILLIAMS, ETHICS AND THE
LIMITS OF PHILOSOPHY (1985).
79. Put more formally "Opponents of consequentialism see the relation
between values and agents as a non-instrumental one: agents are required or at
least allowed to let their actions exemplify a designated value, even if this makes
for a lesser realization of the value overall." Philip Petit, Consequentialism, in A
COMPANION TO ETHICS 230, 231 (Peter Singer ed. 1991). The question is not
whether we need to take consequences into account when making ethical
decisions but whether that is all that we need to do.
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human germ-line modification, person A would maintain that
such courses of action would be wrong.8"
If it is indeed the case that arguments about the genetic
engineering of humans should be conducted solely within a con-
sequentialist framework, the ethical issues are considerably sim-
plified. Deciding whether genetic engineering is right or wrong
now reduces to a series of detailed, in-depth studies of particular
cases. Ethicists still have a role to play, but of perhaps greater
importance are scientists and others who know about risks and
safety, while sociologists, psychologists, policy makers, and politi-
cians who know about people's reactions and public opinions
also have a significant role. For remember, to a consequentialist
there are no moral absolutes. What is right is simply determined
by the overall consequences (typically the net difference between
benefits and harms) that flow from a course of action.
VIII. THE VOICE OF THEOLOGY
Some readers may be disappointed at so late an introduction
into this article of a section specifically addressing theological
concerns. Others, though, may wonder what the contribution of
theology to the debate about genetic engineering can be given
that the world's great religions have nothing explicit to say on
the subject. Although this latter point has a certain validity, the
world's great religions do have a great deal to say about such
issues as creation, our use of the natural world and human
responsibility, all of which clearly connect with genetic engineer-
ing. In addition, it is worth noting that even in countries, such as
the United Kingdom, where only some ten percent of people
regularly worship, surveys indicate that a significant number of
people object to genetic engineering on the grounds that it is
against God's will or contrary to their religious beliefs."s So theo-
80. The question as to whether person A should campaign for laws to be
passed banning germ-line modification is a slightly different one. It is possible
for a person to believe that a course of action is always wrong yet not to
campaign that it should be made illegal. For example, many religious
believers-though not all!-would today hold that failing to worship God is
wrong without wishing to make such worship a legal requirement.
81. A 1992 study of 1228 telephone interviews in the United States
showed that the more important a person's religion was to them, the more
likely they were to believe that genetic engineering was wrong. See T.J. HOBAN
& P.A. KENDALL, CONSUMER ATTITUDES ABOUT THE USE OF BIOTECHNOLOGY IN
AGRICULTURE AND FOOD PRODUCTION (1992). The same survey showed that
while the most common reason for opposing biotechnology involved concerns
that it would "threaten the balance of nature," a significant proportion
mentioned that biotechnology was "not natural," somehow "against God's will"
or "contrary to [their] religious beliefs." Id. It is difficult to quantify the
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logical concerns about genetic engineering matter because many
people have them.
Genetic engineering is increasingly being examined from a
theological perspective, though most of what has been written is
the product of Christian writers." Three main approaches can
be identified: rejection, hesitancy, and acceptance with caveats.
Some authors reject genetic engineering on the grounds
that genetic engineering entails humans having too much power
over animals. Andrew Linzey, for example, considers genetic
engineering to be a form of slavery:
[G]enetic engineering represents the concretisation of the
absolute claim that animals belong to us and exist for us.
We have always used animals, of course, either for food,
fashion or sport. It is not new that we are now using ani-
mals for farming, even in especially cruel ways. What is new
is that we are now employing the technological means of absolutely
subjugating the nature of animals so that they become totally and
completely human property.83
One obvious problem with this argument is that certain ani-
mals, not to mention plants, have been considered human prop-
erty in practically every society since time immemorial. Farm
animals and pets, in particular, are always owned by people.
Another possible reason for rejecting genetic engineering is
that it involves too exploitative a view not just of animals but of
all of nature. Martin Heidegger argued that in technology we
make objects according to some blueprint that we determine.8 4
importance of religious beliefs to such attitudes, but similar studies in New
Zealand, Japan, and Europe also show that religious beliefs are among the most
widely cited reasons why some people consider genetic engineering to be
unacceptable. See P. K COUCHMAN & K FINK-JENSEN, PUBLIC ATTITUDES TO
GENETIC ENGINEERING IN NEW ZEALAND (1990); Bernard Dixon, Biotechnology a
Plus According to European Poll 9 BIO/TECH. 16 (1991); Daryl R.J. Macer, Public
Acceptance of Human Gene Therapy and Perceptions of Human Genetic Manipulation,
3 HUMAN GENE THERAPY 511 (1992); European Commission Directorate-General
XII for Science, Research and Development, BIOTECHNOLOGY- EUROPEAN OPINIONS
ON MODERN BIOTECHNOLOGY - EUROBAROMETER 46.1 (1997).
82. See COLE-TuRNER, supra note 71; DEANE-DRUMMOND, supra note 62;
NELSON, supra note 59; PETERS, supra note 62; REISS & STRAUGHAN, supra note 6;
Anthony Dyson, Genetic Engineering in Theology and Theological Ethics, in ETHICS
AND BIOTECHNOLOGY 259 (Anthony Dyson & John Harris eds., 1994).
83. Andrew Linzey, Human and Animal Slavery: A Theological Critique of
Genetic Engineering, in THE BIo-REVOLUTION: CORNUCOPIA OR PANDORA'S Box
175, 180 (Peter Wheale & Ruth McNally eds., 1990). See also ANDREW LINZEY,
ANIMAL THEOLOGY (1994); Hugh Montefiore, Rights In Animals, CHURCH TIMES,
Feb. 19, 1993.
84. See generally MARTIN HEIDEGGER, THE QUESTION CONCERNING
TECHNOLOGY AND OTHER ESSAYS (William Lovitt trans., 1977).
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We design things to satisfy our purposes rather than allow our
purposes to be affected by, and find creative expression through,
the qualities of the objects themselves. Heidegger's point is par-
ticularly apposite when applied to genetically engineered
organisms.
The most frequent response by religious writers to the issue
of genetic engineering is one of caution or hesitancy. In particu-
lar, some people may hesitate about the movement of genes
between humans and other species, fearing that this somehow
diminishes the distinctiveness of being human. For example, the
notion that humans are made imago Dei may cause some with a
Christian faith to feel uncomfortable about a technology that
apparently threatens to blur the dividing line between humans
and the rest of the created order.8 5 Of course, others may feel
differently, perhaps believing that all of creation is, in a way,
imago Dei; for how can that which is created do other than reflect
its creator, sustainer, and redeemer?
Finally, though this category overlaps with the previous one,
there are religious writers who accept genetic engineering,
though typically with certain specific caveats. Phil Challis, argu-
ing against Andrew Linzey's rejection of genetic engineering
considered above, writes
We are co-creators with God, "fearfully and wonderfully
made" (Ps 139:14). With our finite freedom we are called
by Him to act responsibly as we continue the process of
genetic manipulation of domestic organisms. A theology
that emphasizes embodiment rather than body-spirit
dichotomy, that emphasizes becoming rather than immu-
tability as an essential part of God's nature, that empha-
sizes relationship within the web rather than domination
from outside the system, such a Christian theology may
provide a critical framework that can realistically embrace
the potential of genetic engineering for good.8 6
85. See I Corinthians 15:39 (Revised Standard Version) ("For not all flesh
is alike, but there is one kind for men, another for animals, another for birds,
and another for fish.").
86. PHIL CHALLis, GENETIC ENGINEERING AND ITS APPLICATIONS: SOME
THEOLOGICAL AND ETHICAL REFLECTIONS 3940 (1992). Celia Deane-Drummond
argues that "[a] theological approach encourages those involved to see the
wider social and religious consequences of these decisions. It does not
necessarily ban all genetic engineering, but seeks to transform it so that it more
clearly represents a fully human enterprise." Celia Dean-Drummond, Reshaping
Our Environment: Implications of the New Biotechnology, 5 THEOLOGY IN GREEN 19,
26 (1995).
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Ronald Cole-Turner has explored the implications of a dis-
tinction between humans as co-creators with God-a concept
which, he feels, contains a number of difficulties-and humans
as participants, through genetic engineering, in redemption.87
Here redemption is being used in the sense of "restoration."
The idea is that genetic engineering can help to overcome
genetic defects caused by harmful mutations. In this way genetic
engineering can help to restore creation to a fuller, richer exist-
ence and can, Cole-Turner maintains, play an important role
without encroaching on the scope of divine activity.
It can perhaps be argued, in this vein, that humans may have
a theological responsibility, even a duty, to use genetic engineer-
ing to root out imperfections in the natural world, including
those found in humans. Viewed in this light, genetic engineer-
ing can be seen as a tool with the potential to eliminate harmful
genetic mutations, reduce suffering, and restore creation to its
full glory.
IX. SEEKING CONSENSUS
We live in an increasingly pluralistic society. Within all West-
ern countries there is no longer a single shared set of moral val-
ues. Even the various religions disagree on ethical matters and
many people no longer accept any religious teaching.
Nevertheless, there is still great value in taking seriously the
various traditions-religious and otherwise-that have given rise
to ethical conclusions. People do not live their lives in isolation:
they grow up within particular moral traditions. Even if we end
up departing somewhat from the values we received from our
families and those around us as we grew up, none of us derives
our moral beliefs from first principles, ex nihilo as it were. In the
particular case of moral questions concerning biotechnology, a
tradition of ethical reasoning is already beginning to accumu-
late. 8 Many countries have official committees or other bodies
looking into the ethical issues that surround at least some
instances of biotechnology.89 The tradition surrounding ethical
reasoning in this field is nothing like as long established as, for
example, the traditions surrounding such questions as abortion,
'87. See generally COLE-TURNER, supra note 71.
88. See generally Michael J. Reiss, Ethical Issues, in 224 CONFERENCE OF
ROYAL SOCIETY OF MEDICINE: GENETIC ENGINEERING IN FOOD PRODUCTUCTION
165 (Lord Soulsby of Swaffham Prior ed., 1997).
89. See generally BIOTECHNOLOGY INDUSTRY ORGANIZATION, STATEMENT OF
PRINCIPLES (not dated); EUROPABIO, EUROPABIo'S CORE ETHICAL VALUES
(1998).
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euthanasia, war, and trade protectionism. Nevertheless, there is
the beginning of such a tradition and similar questions are being
debated in many countries across the globe."
Given, then, the difficulties in relying solely on either reason
or any one particular ethical tradition, we are forced to consider
the approach of consensus.9' It is true that consensus does not
solve everything. After all, what does one do when consensus
cannot be arrived at? Nor can one be certain that consensus
always arrives at the right answer-a consensus once existed that
women should not have the vote. Nonetheless, there are good
reasons both in principle and in practice in searching for consen-
sus. Such a consensus should be based on reason and demo-
cratic debate and take into account long established practices of
ethical reasoning. At the same time, it should be open to criti-
cism and refutation and the possibility of change. Finally, con-
sensus should not be equated with majority voting.
Consideration needs to be given to the interests of minorities,
particularly if they are especially affected by the outcomes, and to
those-such as young children, the mentally infirm and non-
humans-unable to participate in the decision-making process.
X. CONCLUSION
Somatic gene therapy for a number of medical conditions,
such as cystic fibrosis, is beginning to offer the realistic possibility
of improving physical health, relieving stress, worry, and other
psychological problems, and reducing the number of abortions.
Further, it is not significantly different, in principle, from other
medical treatments. Those who accept conventional medicine-
the overwhelming majority of people-should have no qualms
about accepting the benefits of somatic gene therapy provided it
is shown to be safe and efficacious.
However, the likely benefits of somatic gene therapy should
not be overstated. Most human disease will not be eliminated
through its adoption. In time somatic gene therapy is likely to
prove to be just one of a number of important therapeutic
approaches used in the prevention and treatment of human
disease.
At present, germ-line therapy is unsafe. In time, though,
this may change. In my opinion the ethical arguments in favor of
90. See generally EUROPABIo, supra note 89.
91. See generally id. See also JONATHAN D. MORINO, DECIDING TOGETHER:
BIOETHICS AND MORAL CONSENSUS (1995); Lady Warnock, Religion, Morality and
Human Reproductive Technology, in 2 FARMINGTON PAPERS PHILOSOPHY OF
RELIGION (1998).
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a total, unconditional, 'and permanent ban on germ-line therapy
are not overwhelming. There may prove to be strong arguments
in favor of the careful use of germ-line therapy to alleviate suffer-
ing in certain circumstances.
For the foreseeable future it is probably best to outlaw the
use of either somatic or germ-line modification to enhance
human traits. In time such applications of genetic engineering
may be practicable, safe, and desirable. However, not everyone
will agree on what changes, if any, should be made. In such cir-
cumstances it would be better to err on the side of caution.
